Literature DB >> 19960431

Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005.

Kåre G Sunesen1, Mette Nørgaard, Ole Thorlacius-Ussing, Søren Laurberg.   

Abstract

Compromised immune function may increase the risk of anal squamous cell carcinoma (SCC). We examined the risk of anal SCC in patients with HIV infection and other chronic disorders associated with immunosuppression. A population-based cohort study was conducted using the Danish National Patient Registry and the Danish Cancer Registry (DCR). We identified all patients with a first-time hospital contact or procedure for HIV infection, solid organ transplantation or autoimmune disease or a first-time record of haematologic malignancy in the DCR, 1978-2005, and followed these for a subsequent anal SCC, starting follow-up 1 year after diagnosis of the index disease. Standardised incidence ratios (SIRs) were computed as the ratio of observed to expected numbers of anal SCCs, based on national age-, sex- and period-specific rates. Among 4,488 patients with HIV, we observed 21 anal SCCs with 0.3 expected (SIR: 81.1 (95% confidence interval (CI): 51.6-121.9)). Risk of anal SCC was markedly increased among 5,113 solid organ recipients (SIR: 14.4 (CI: 7.0-26.4)) and 30,165 patients with haematologic malignancies (SIR: 2.3 (CI: 1.1-4.2)) but only moderately increased among 242,114 patients with autoimmune diseases (SIR: 1.3 (CI: 1.0-1.6)). SIRs varied according to type of autoimmune disease and were high in patients with Crohn's disease (SIR: 3.1 (CI: 1.2-6.4)), psoriasis (SIR: 3.1 (CI: 1.8-5.1)), polyarteritis nodosa (SIR: 8.8 (CI: 1.5-29.0)) and Wegener's granulomatosis (SIR: 12.4 (CI: 2.1-40.8)). In conclusion, we found HIV infection, solid organ transplantation, haematologic malignancies and a range of specific autoimmune diseases strongly associated with increased risk of anal SCC.

Entities:  

Mesh:

Year:  2010        PMID: 19960431     DOI: 10.1002/ijc.25080

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

1.  Anal Squamous Cell Carcinoma: An Infrequent Challenge in the Management of Ulcerative Colitis Under Combination Therapy.

Authors:  Paulo Gustavo Kotze; Patricia Zacharias
Journal:  J Crohns Colitis       Date:  2016-01-27       Impact factor: 9.071

Review 2.  Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach.

Authors:  Van Morris; Cathy Eng
Journal:  J Gastrointest Oncol       Date:  2016-10

Review 3.  Screening for Anal Cancer in Women.

Authors:  Anna-Barbara Moscicki; Teresa M Darragh; J Michael Berry-Lawhorn; Jennifer M Roberts; Michelle J Khan; Lori A Boardman; Elizabeth Chiao; Mark H Einstein; Stephen E Goldstone; Naomi Jay; Wendy M Likes; Elizabeth A Stier; Mark L Welton; Dorothy J Wiley; Joel M Palefsky
Journal:  J Low Genit Tract Dis       Date:  2015-07       Impact factor: 1.925

4.  Human papillomavirus vaccination in males: the state of the science.

Authors:  Luis F Barroso; Timothy Wilkin
Journal:  Curr Infect Dis Rep       Date:  2011-04       Impact factor: 3.725

5.  Malignancy risk in vasculitis.

Authors:  Tanaz A Kermani; Kenneth J Warrington; Shreyasee Amin
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-02       Impact factor: 5.346

6.  Long-standing Crohn's disease and its implication on anal squamous cell cancer management.

Authors:  Amy L Lightner; Sara B Moncrief; Thomas C Smyrk; John H Pemberton; Michael G Haddock; David W Larson; Eric J Dozois; Kellie L Mathis
Journal:  Int J Colorectal Dis       Date:  2017-03-14       Impact factor: 2.571

Review 7.  Squamous cell carcinoma of the anus-an opportunistic cancer in HIV-positive male homosexuals.

Authors:  Pascal Gervaz; Alexandra Calmy; Ymer Durmishi; Abdelkarim S Allal; Philippe Morel
Journal:  World J Gastroenterol       Date:  2011-07-07       Impact factor: 5.742

8.  Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal.

Authors:  Van K Morris; Asif Rashid; Miguel Rodriguez-Bigas; Prajnan Das; George Chang; Aki Ohinata; Jane Rogers; Christopher Crane; Robert A Wolff; Cathy Eng
Journal:  Oncologist       Date:  2015-09-17

9.  Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.

Authors:  Lars Toft; Martin Tolstrup; Martin Müller; Peter Sehr; Jesper Bonde; Merete Storgaard; Lars Østergaard; Ole S Søgaard
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

Review 10.  Optimal treatment strategies for anal cancer.

Authors:  Shahab Ahmed; Cathy Eng
Journal:  Curr Treat Options Oncol       Date:  2014-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.